Victhom and Otto Bock sign partnership agreement to establish joint venture for Neurobionix ...(s bionic devices involved in the treatme...)

Date:4/30/2009

s bionic devices involved in the treatment of a variety of physical and physiological dysfunctions. Victhom's Neurobionix division focuses on the development and commercialization of technologies and products involving implantable devices that feature neurosensing and neurostimulation components, integrated with artificial intelligence. Victhom's Biotronix division develops biomechatronic products to support or replace peripheral limbs in what is known as the orthotics and prosthetics market.

About Otto Bock

Otto Bock HealthCare is a global market leader in prosthetics and is on a steady growth course thanks to its leading technology for people. The company has been owner-managed ever since it was founded in 1919. With headquarters in Duderstadt, Germany, Otto Bock HealthCare has subsidiaries in 40 countries and employs 4,000 people around the world. In 2008, the company's sales reached (euro)479 million, representing a currency-adjusted growth of 9.2%.

The company has been active in the North American market since 1958, when Otto Bock USA subsidiary was founded in Minneapolis. Otto Bock HealthCare has also been represented in Canada through its Toronto subsidiary since 1978.

The company has a global infrastructure in the field of neurostimulation and offers sales, services and medical consulting. Vienna, Austria is a key neurostimulation research platform for Otto Bock HealthCare. The company is headed by President and CEO Professor Hans Georg Näder.

FORWARD-LOOKING STATEMENTS

Some of the statements made herein may constitute forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause Victhom's actual results, performance or achievements to be materially different from those expressed or implied by any of Victhom's statements. Actual events or results may
'/>"/>

SOURCE VICTHOM HUMAN BIONICS INC. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5
Related biology technology :

1. Victhom announces the filing of a patent application to address sudden unexplained death in epilepsy (SUDEP)
2. Victhom Human Bionics Receives CE Mark for the Neurostep(TM) System, the Worlds First Fully Implantable Closed-Loop Neuromodulation Therapy for Treatment of Foot Drop
3. Victhom Human Bionics Neurobionix Division receives ISO 13485:2003 Certification for its Design Control System
4. Victhom announces the completion of the second phase of the apnea therapy development
5. Victhom Announces Launch of Enhanced Company Website
6. Victhom to Participate in the OneMedPlace Finance Forum
7. Victhom announces promising results on the proof of concept for its unique closed-loop neuromodulation system
8. DATATRAK International, Inc. Forms Strategic Partnership with Inclinix, Inc.
9. ImQuest BioSciences and Arisyn Therapeutics Announce Strategic Partnership to Develop Infectious Disease and Cancer Drugs
10. E&K Scientific Announces Partnership with Sciformatix
11. PRA International Presents Key Budgeting Strategies at 18th Annual CRO Partnerships Conference